ReviewTrends in molecular medicine2009
Brain cancer propagating cells: biology, genetics and targeted therapies.
Review in Trends in molecular medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 116 citations in OpenAlex.
- The role of targeted therapies in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.Journal of neuro-oncology · 2014Guideline
- Clinical GBM hybrid artificial intelligence for prescription dose recommendation and outcome prediction after gamma knife radiosurgery treatment: a proof-of-concept.Frontiers in oncology · 2026Article
- Network analysis to identify driver genes and combination drugs in brain cancer.Scientific reports · 2024Article
- Juglone induces ferroptosis in glioblastoma cells by inhibiting the Nrf2-GPX4 axis through the phosphorylation of p38MAPK.Chinese medicine · 2024Article
- EGFL7 expression profile in IDH-wildtype glioblastomas is associated with poor patient outcome.Journal of pathology and translational medicine · 2022Article
- Antiproliferative effect of GTS-21 in glioblastoma cells.Oncology letters · 2021Article
- The multilayer community structure of medulloblastoma.iScience · 2021Article
- N-cadherin upregulation mediates adaptive radioresistance in glioblastoma.The Journal of clinical investigation · 2021Article
- Intracellular Autofluorescence as a New Biomarker for Cancer Stem Cells in Glioblastoma.Cancers · 2021Article
- Potential lethal damage repair in glioblastoma cells irradiated with ion beams of various types and levels of linear energy transfer.Journal of radiation research · 2019Article
- Combination therapy to checkmate Glioblastoma: clinical challenges and advances.Clinical and translational medicine · 2018Review
- The Invasive Region of Glioblastoma Defined by 5ALA Guided Surgery Has an Altered Cancer Stem Cell Marker Profile Compared to Central Tumour.International journal of molecular sciences · 2017Article
- Crizotinib targets in glioblastoma stem cells.Cancer medicine · 2017Article
- Systemic metastases from central nervous system ependymoma: case report and review of the literature.The neuroradiology journal · 2017Review
- Small G protein Rac GTPases regulate the maintenance of glioblastoma stem-like cells in vitro and in vivo.Oncotarget · 2017Article
- Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells.Oncotarget · 2016Article
- The availability of the embryonic TGF-β protein Nodal is dynamically regulated during glioblastoma multiforme tumorigenesis.Cancer cell international · 2016Article
- MiR-449a exerts tumor-suppressive functions in human glioblastoma by targeting Myc-associated zinc-finger protein.Molecular oncology · 2015Article
- Involvement of the neural stem cell compartment by pediatric and adult gliomas: a retrospective review of 377 cases.Journal of neuro-oncology · 2015Article
- A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.Disease models & mechanisms · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Cancer propagating cells (CPCs) within primary central nervous system (CNS) tumors (glioblastoma multiforme (GBM), medulloblastoma (MB) and ependymoma) might be integral to tumor development and perpetuation. These cells, also known as brain cancer propagating cells (BCPCs), have the ability to self-renew and proliferate. BCPCs can initiate new tumors in mice with high efficiency and these exhibit many features that are characteristic of patient's brain tumors. Accumulating evidence suggests that BCPCs might originate from the transformation of neural stem cells (NSCs) and their progenitors. Furthermore, recent studies have shown that NSC surface markers also define BCPCs. Ultimately, treatments that include specific targeting of BCPCs might potentially be more effective at treating the entire tumor mass, translating to improved patient survival and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.